Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
TNG-462 by Tango Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
TNG-462 is under clinical development by Tango Therapeutics and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Data Insights
TNG-462 by Tango Therapeutics for Soft Tissue Sarcoma: Likelihood of Approval
TNG-462 is under clinical development by Tango Therapeutics and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData,...